New drug combo aims to shrink mouth cancer before surgery
NCT ID NCT06448026
First seen Jun 26, 2026 · Last updated Jul 31, 2026 · Updated 3 times
Summary
This phase 2 trial tests whether giving two drugs, cemiplimab and cetuximab, before salvage surgery can help control recurrent oral cavity squamous cell carcinoma. The study involves 17 adults whose cancer has returned at least 3 months after prior treatment. Researchers will monitor safety and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Cemiplimab and cetuximab
- What this could lead to
- If it works, this combination could help shrink tumors before surgery, potentially improving outcomes for people with recurrent mouth cancer.
- What could go wrong
- This is a very small, early-phase trial with only 17 participants. The drugs may cause side effects, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV-NEGATIVE OROPHARYNGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.